HER2/neu peptide-based vaccines, with GM-CSF as an adjuvant, in patients with advanced-stage HER2/neu-expressing cancers.
Schiffman
K
K
Division of Oncology, University of Washington, Seattle, Washington 98195, USA.
Disis
M L
ML